<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052416</url>
  </required_header>
  <id_info>
    <org_study_id>BIDMC-W-01-0384-FB</org_study_id>
    <secondary_id>CDR0000258419</secondary_id>
    <secondary_id>NEDH-W-01-0384-FB</secondary_id>
    <secondary_id>BIDMC-2001-P-001950</secondary_id>
    <secondary_id>NCI-V02-1714</secondary_id>
    <nct_id>NCT00052416</nct_id>
  </id_info>
  <brief_title>Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Thalidomide in Indolent Non-Hodgkin's Lymphoma: A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor.&#xD;
&#xD;
      PURPOSE: Phase I trial to determine the effectiveness of thalidomide in treating patients who&#xD;
      have asymptomatic, indolent non-Hodgkin's lymphoma or chronic lymphocytic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility, in terms of toxicity and patient compliance, of thalidomide&#xD;
           in patients with asymptomatic, indolent non-Hodgkin's lymphoma or chronic lymphocytic&#xD;
           leukemia.&#xD;
&#xD;
        -  Determine the event-free and progression-free survival of patients treated with this&#xD;
           drug.&#xD;
&#xD;
        -  Determine disease response and time to next treatment in patients treated with this&#xD;
           drug.&#xD;
&#xD;
        -  Determine the quality of life of patients treated with this drug.&#xD;
&#xD;
      OUTLINE: Patients receive oral thalidomide once daily. Treatment continues for 18 months in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Quality of life is assessed at baseline, monthly during study, and at the end of the study.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30-36 patients will be accrued for this study within 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">January 2003</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thalidomide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed indolent lymphoma or leukemia of one of the following&#xD;
             subtypes:&#xD;
&#xD;
               -  Chronic lymphocytic leukemia&#xD;
&#xD;
               -  Follicular center lymphoma (grade I or II)&#xD;
&#xD;
               -  Lymphoplasmacytic lymphoma&#xD;
&#xD;
               -  Marginal zone lymphoma (nodal, extranodal, or splenic)&#xD;
&#xD;
               -  Small lymphocytic lymphoma&#xD;
&#xD;
               -  Waldenstrom's macroglobulinemia&#xD;
&#xD;
          -  Any stage of disease allowed&#xD;
&#xD;
          -  No hairy cell leukemia&#xD;
&#xD;
          -  No T-cell lymphomas&#xD;
&#xD;
          -  No prior treatment for lymphoma/leukemia&#xD;
&#xD;
          -  Considered appropriate for expectant management&#xD;
&#xD;
               -  Must not require cytotoxic therapy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin greater than 10.0 g/dL&#xD;
&#xD;
          -  Platelet count greater than 75,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 2 times normal&#xD;
&#xD;
          -  AST and ALT no greater than 2 times normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  No unstable coronary artery disease&#xD;
&#xD;
          -  No myocardial infarction in the past 6 months&#xD;
&#xD;
          -  No serious or uncontrolled arrhythmias&#xD;
&#xD;
          -  No history of thromboembolic disease&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No asthma or chronic obstructive pulmonary disease requiring the use of home oxygen or&#xD;
             frequent oral steroids (prednisone greater than 20 mg per day for 5 days within the&#xD;
             past 3 months)&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Not planning to become pregnant in the next 2 years&#xD;
&#xD;
          -  Fertile female patients must use 1 highly effective method and 1 additional effective&#xD;
             method of contraception for 1 month prior to, during, and for 1 month after study&#xD;
             participation&#xD;
&#xD;
          -  Male patients must use effective barrier contraception during and for 1 month after&#xD;
             study participation&#xD;
&#xD;
          -  Willing and able to participate in the S.T.E.P.S. (System for Thalidomide Education&#xD;
             and Prescribing Safety) program&#xD;
&#xD;
          -  No contraindications to meeting the requirements of the S.T.E.P.S. program&#xD;
&#xD;
          -  No other prior malignancy except curatively treated non-melanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No peripheral neuropathy&#xD;
&#xD;
          -  No poorly controlled diabetes defined by either of the following:&#xD;
&#xD;
               -  Glycosylated hemoglobin greater than 8.0 g/dL&#xD;
&#xD;
               -  Known end organ disease (i.e., nephropathy, retinopathy, or neuropathy)&#xD;
&#xD;
          -  No other concurrent illness that would preclude study therapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robin Joyce, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care - University Health Center Campus</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2003</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 25, 2013</last_update_submitted>
  <last_update_submitted_qc>June 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2013</last_update_posted>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>stage 0 chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>Waldenstr√∂m macroglobulinemia</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

